Results 21 to 30 of about 15,810 (189)

Physicochemical Compatibility of Ceftolozane-Tazobactam with Parenteral Nutrition. [PDF]

open access: yesPharmaceuticals (Basel)
Ceftolozane-tazobactam (CT) is used for the treatment of complicated infections and for multidrug-resistant strains of Pseudomonas aeruginosa and extended-spectrum beta-lactamase-producing enterobacteria. In certain cases, simultaneous administration of CT and parenteral nutrition (PN) may be required, but compatibility of Y-site co-administration is ...
De Pourcq JT   +7 more
europepmc   +8 more sources

Use of Ceftolozane-Tazobactam in Patient with Severe Medium Chronic Purulent Otitis by XDR Pseudomonas aeruginosa

open access: yesCase Reports in Infectious Diseases, 2019
We present a case of a male Italian patient of 66 years with a history of kidney transplantation in treatment with cyclosporine and methylprednisolone. He visited an ENT clinic and was diagnosed as chronic left purulent otitis media.
L. M. Saraca   +5 more
doaj   +2 more sources

Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination

open access: yesInfection and Drug Resistance, 2013
Mai-Chi Hong1, Donald I Hsu1,2, Mark Bounthavong3,41Department of Pharmacy Practice and Administration, Western University of Health Sciences, Pomona, 2Department of Pharmacy, St Joseph Hospital, Orange, 3Department of Pharmacy, Veterans Affairs San ...
Hong MC, Hsu DI, Bounthavong M
doaj   +1 more source

Evaluation of in vitro activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against Enterobacterales and Pseudomonas aeruginosa—the EM200 study

open access: yesNew Microbes and New Infections, 2021
Ceftolozane-tazobactam is a cephalosporin/β-lactamase inhibitor combination developed for use against some β-lactam- and multidrug-resistant Gram-negative organisms.
J. Belkhair   +5 more
doaj   +1 more source

Safety and efficacy of ceftolozane/tazobactam plus metronidazole versus meropenem from a phase 2, randomized clinical trial in pediatric participants with complicated intra-abdominal infection [PDF]

open access: yes, 2023
BACKGROUND: Ceftolozane/tazobactam, a cephalosporin-β-lactamase inhibitor combination, is approved for the treatment of complicated urinary tract infections and complicated intra-abdominal infections (cIAI).
Popejoy, Myra W   +23 more
core   +1 more source

Ceftolozane/tazobactam disrupts Pseudomonas aeruginosa biofilms under static and dynamic conditions. [PDF]

open access: yesJ Antimicrob Chemother
Background Pseudomonas aeruginosa biofilms limit the efficacy of currently available antibacterial therapies and pose significant clinical challenges.
Kostoulias X   +13 more
europepmc   +2 more sources

Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane/tazobactam: an ex vivo and in vivo study

open access: yesJournal of Translational Medicine, 2020
Background Extracorporeal membrane oxygenation (ECMO) is increasingly used in intensive care units and can modify drug pharmacokinetics and lead to under-exposure associated with treatment failure. Ceftolozane/tazobactam is an antibiotic combination used
Camille Mané   +9 more
doaj   +1 more source

Evaluation of in vitro activity of ceftolozane–tazobactam against recent clinical bacterial isolates from Brazil – the EM200 study

open access: yesBrazilian Journal of Infectious Diseases, 2020
Background: The emergence of antibiotic resistance is increasing and there are few effective antibiotics to treat infections caused by resistant and multidrug resistant bacterial pathogens.
Felipe Francisco Tuon   +4 more
doaj   +1 more source

Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem

open access: yesCritical Care, 2022
Background Ceftolozane/tazobactam, a combination antibacterial agent comprising an anti-pseudomonal cephalosporin and β-lactamase inhibitor, is approved for the treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) in ...
Marin H. Kollef   +7 more
doaj   +1 more source

Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections

open access: yesTherapeutics and Clinical Risk Management, 2016
Stephanie E Giancola,1 Monica V Mahoney,2 Tiffany E Bias,3,4 Elizabeth B Hirsch2,51Department of Pharmacy, St Mary’s Medical Center, Huntington, WV, 2Beth Israel Deaconess Medical Center, Boston, MA, 3Hahnemann University Hospital, 4Drexel ...
Giancola SE   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy